PIK3CB and ovarian carcinoma: In ovarian cancer, the PI3K/Akt signalling pathway is dysregulated due to mutations in PI3K, PI3KCA, and PTEN deletion, in the regulatory and catalytic domains, or due to modifications of downstream targets of PI3K [59,60,61,62].